Claims
- 1. A method for treating an autoimmune disease selected from the group consisting of multiple sclerosis, Graves' disease, systemic lupus erythematosus, diabetes mellitus, aseptic meningitis, systemic scleroderma, adult onset idiopathic hypoparathyroidism, and membranous glomerulonephritis, comprising:
testing a group of patients having said autoimmune disease for elevated levels of expressed T-cell surface CD26 relative to the levels of expressed T-cell surface CD26 of a normal person; selecting from the group one or more patients having elevated levels of T-cell surface CD26; and then administrating to the selected patients a therapeutically effective amount of pentostatin.
- 2. The method according to claim 1, wherein pentostatin is administrated intravenously, intramuscularly, orally, by inhalation, parenterally, intraperitoneally, intraarterially, transdermally, sublingually, nasally, through use of suppositories, transbuccally, liposomally, adiposally, intraocularly, subcutaneously, intraarticularly, intrathecally, topically, or through local administration.
- 3. The method according to claim 1, further comprising administering to the patient an anti-autoimmune disease drug selected from the group consisting of cyclosporin A, methotrexate, cyclophosphamide, azathioprine and steroids.
- 4. The method according to claim 1, further comprising administering to the patient an anti-acid drug.
- 5. The method according to claim 4, wherein the anti-acid drug is cimetidine.
- 6. The method according to claim 1, wherein pentostatin is administrated orally.
- 7. The method according to claim 6, wherein pentostatin is administered in an oral dosage form selected from the group consisting of tablet, pill, dragee, capsule, emulsion, lipophilic and hydrophilic suspension, gel, syrup, and slurry.
- 8. The method according to claim 1, wherein pentostatin is administrated parenterally.
- 9. The method according to claim 8, wherein pentostatin is present in a solution comprising pentostatin.
- 10. The method according to claim 9, wherein the pentostatin is present in a solution that additionally comprises mannitol and sterile water.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation application of Ser. No. 09/620,254, filed Jul. 20, 2000, which is a continuation of Provisional application Serial No. 60/145,365, filed Jul. 22, 1999, both of which are incorporated herein by reference in their entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60145365 |
Jul 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09620254 |
Jul 2000 |
US |
Child |
10742492 |
Dec 2003 |
US |